Early traditional Chinese medicine bundle therapy for the prevention of sepsis acute gastrointestinal injury in elderly patients with severe sepsis

Wang, Yifei; Zhang, Yunhua; Jiang, Rui

doi:10.1038/srep46015

Cited by 20 publications

(23 citation statements)

References 33 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alternative herbal medicines, which are characterized as multiple compounds and targets, exhibit advantages in the treatment of pulmonary fibrosis. Unfortunately, the detailed molecular signaling pathway remains intractable because the potential targets and active substances of herbs are difficult to identify and analyze [ 37 , 38 ]. High-throughput technologies, such as RNA sequencing and network pharmacology, offer approaches for exploring drug targets and identifying potential active ingredients in TCM [ 39 ].…”

Section: Discussionmentioning

confidence: 99%

Feifukang ameliorates pulmonary fibrosis by inhibiting JAK-STAT signaling pathway

Wang

Zhang

et al. 2018

BMC Complement Altern Med

View full text Add to dashboard Cite

BackgroundFeifukang (FFK) is a traditional Chinese medicine composed of herbs that protect lung function. However, difficulty arises regarding the clinical application of FFK due to the complex mechanism of Chinese medicines. This study aimed to investigate the efficacy of FFK and explore its targeted genes and pathways.MethodsHistopathological changes and collagen deposition were measured to evaluate the effect of FFK on bleomycin-induced pulmonary fibrosis in mice. The differentially expressed targeted genes and pathways were first screened using RNA sequencing. Then network pharmacology and other experiments were conducted to confirm RNA sequencing data.ResultsFFK treatment reduced the pathological score and collagen deposition, with a decrease in α-SMA and collagen. RNA sequencing and network pharmacology results all showed that FFK can ameliorate pulmonary fibrosis through multi-genes and multi-pathways. The targeted genes in JAK-STAT signaling pathway are some of the most notable components of these multi-genes and multi-pathways. Further experiments illustrated that FFK regulated phosphorylation of SMAD3, STAT3 and JAK1, and their co-expressed lncRNAs, which all are the important genes in JAK-STAT signaling pathway.ConclusionFFK can ameliorate pulmonary fibrosis by inhibiting JAK-STAT signaling pathway and has potential therapeutic value for lung fibrosis treatment. Our study provides a new idea for the study of traditional Chinese medicine.

show abstract

Section: Discussionmentioning

confidence: 99%

Feifukang ameliorates pulmonary fibrosis by inhibiting JAK-STAT signaling pathway

Wang

Zhang

et al. 2018

BMC Complement Altern Med

View full text Add to dashboard Cite

show abstract

“…A 21-nucleotide siRNA targeting transcription start site (TSS, −9/+10 bp, 5′-GGGCGGAGGAAAGGAGAAAtt-3′) were chosen for HPA1 silencing. 19 The siRNA was chemically synthesized and transfected with Lipofectamine 2000 (Thermo Fisher Scientific) according to the suggested concentration of manufacturer (RiboBio Co. Ltd, Guangzhou, China).…”

Section: Methodsmentioning

confidence: 99%

“…TCM formulae are usually effective alternatives to western medicine for uncertain disorders, including ALI. 19 , 20 For treating ALI, TCM follows the therapeutic concepts of integrated and balanced treatment. Fusu agent is a newly developed oral medicine used in clinical practice in China to treat sepsis-associated ALI.…”

Section: Introductionmentioning

confidence: 99%

The therapeutic effects of traditional Chinese medicine Fusu agent in LPS-induced acute lung injury model rats

Gao¹,

Zhao²,

Zhang³

et al. 2018

DDDT

View full text Add to dashboard Cite

PurposeAcute lung injury (ALI) is a common and fatal oxidative stress in the lung, mainly induced by endothelial injury and capillary leakage. In our previous study, “Fusu agent”, a traditional Chinese medicine, was found to exert preventive effect on endothelial damage in lipopoly-saccharide (LPS)-induced ALI model rats partially via inhibiting heparanase1 (HPA1) activation and inhibiting the inflammatory factors. However, it is still unknown whether Fusu agent exerts its therapeutic effect in LPS-induced ALI model rats and its potential mechanism.Materials and methodsRats were injected with LPS (3 mg/kg, intraperitoneally) to induced ALI, and the prepared Fusu agent was given (2, 4 or 6 g/kg) 2 hours after LPS challenge. Twenty-four or 48 hours after Fusu agent administration, the biochemical changes in the plasma and lung tissues and the morphological/histological changes in the lung associated with inflammation and injury were evaluated. Human umbilical vein endothelial cells (HUVECs) were employed to confirm the therapeutic effects of Fusu agent and investigate its mechanisms, that is, affecting ROS accumulation, mitochondrial transmembrane potential (MTP) maintenance and decreasing the expression levels of HPA1.ResultsAdministration of Fusu agent obviously improved the lung injury and recovered vascular endothelium loss and injury. CD31 signal, which is a specific marker for endothelial vascular lesions, was decreased after Fusu agent treatment in LPS-induced ALI model rats, indicating its therapeutic effect against endothelial surface layer injury. Meanwhile, Fusu agent also decreased HPA1 expression and inflammatory responses. In vitro, Fusu agent-medicated serum decreased injury and cell death induced by LPS in HUVECs by stabilizing MTP and decreasing the leakage of lactate dehydrogenase. Consistently, Fusu agent-medicated serum downregulated HPA1 induced by LPS stimulation.ConclusionThese findings suggest that Fusu agent exerts its therapeutic effect in both LPS-induced ALI model rats and HUVECs potentially via suppressing HPA1 expression, and thus exerts prosurvival effect via maintaining MTP and attenuating cell injury.

show abstract

“…[7,20] Another study proves that acupuncture, along with Chinese herbal medicine, can decrease acute GI injury incidence in elderly patients with severe sepsis. [21]…”

Section: Introductionmentioning

confidence: 99%

Acupuncture effect on digestion in critically ill postoperative oral and hypopharyngeal cancer patients

Ben-Arie

Kao

et al. 2019

Medicine

View full text Add to dashboard Cite

Introduction:Head and neck cancer patients are at a high risk to suffer from malnourishment, a risk that increases in postoperative condition and with the use of enteral nutrition (EN). Until now patients who are suffering from indigestion in the intensive care unit (ICU) received treatment in the form of prokinetic drugs, drugs that can lead to serious side effects and only can partially improve digestion functions. Acupuncture was used successfully in several clinical trials to improve postoperative indigestion in cancer patients without any reported adverse events. The study aims are to investigate acupuncture effect in combination with prokinetic drugs in the treatment of indigestion in postoperative oral and hypopharyngeal cancer patients in the ICU.Methods:Single-center, double-blind randomized control trial will compare between 2 equal groups. A total of 28 patients that will meet the inclusion criteria: age 30 to 80, postplastic surgery for oral cancer or hypopharyngeal cancer, developed feeding intolerance 2 times in the first postoperative day, Apache score <20, and needed EN. Patients will be randomly divided (1:1) into treatment group or control group for 3 treatments in 3 days along with routine ICU treatment. The main outcome measurement will be the number of days a patient needs to reach his total energy expenditure.Expected outcome:The results will shed light on the effectiveness and safety of acupuncture in a double-blind design treating postoperative ICU cancer patients. In addition, the study presents a revolutionary double-blind design that if, will prove as successful might influence the way double-blind acupuncture studies are performed today.Other information:The study will be conducted in the surgical ICU department, of China medical university hospital, Taichung 404, Taiwan. The study is conducted on stable ICU patients and is anticipated to have minimum risk for adverse events. Patients enrollment and data collection will start from May 15, 2019. The study expected completion time: June 2021.

show abstract

Early traditional Chinese medicine bundle therapy for the prevention of sepsis acute gastrointestinal injury in elderly patients with severe sepsis

Cited by 20 publications

References 33 publications

Feifukang ameliorates pulmonary fibrosis by inhibiting JAK-STAT signaling pathway

Feifukang ameliorates pulmonary fibrosis by inhibiting JAK-STAT signaling pathway

The therapeutic effects of traditional Chinese medicine Fusu agent in LPS-induced acute lung injury model rats

Acupuncture effect on digestion in critically ill postoperative oral and hypopharyngeal cancer patients

Contact Info

Product

Resources

About